Table 5.
UK National External Quality Assurance Scheme (UK NEQAS) return data from the coeliac disease (CD) serology scheme distributions 115, 121 and 122 across all methods. Tissue transglutaminase (TTG)2 results have been normalized to multiples upper limit of normal (ULN) for each method.
| Method | Valid returns | All-laboratory mean (021×ULN) | Lowest (×ULN) | Highest (×ULN) | Proportion>10 × ULN | Proportion<10 × ULN | |
|---|---|---|---|---|---|---|---|
| Distribution 115 | All methods | 269 | 3·0 | 1·5 | 21·8 | 6% | 94% |
| Inova | 27 | 8·4 | 1·5 | 21·8 | 55·6% | 44·4% | |
| Phadia 250 | 154 | 2·3 | 1·6 | 3·4 | 0·0% | 100·0% | |
| Orgentec | 41 | 1·5 | 1·1 | 1·8 | 0·0% | 100·0% | |
| Euroimmun | 17 | 5·1 | 3·7 | 7·1 | 0·0% | 100·0% | |
| Phadia Varelisa | 18 | 1·5 | 1·0 | 2·8 | 0·0% | 100·0% | |
| Aesku | 12 | 3·9 | 1·5 | 7·5 | 0·0% | 100·0% | |
| Distribution 121 | All methods | 299 | 8·4 | 1·6 | 39·7 | 22% | 78% |
| Inova | 31 | 19·3 | 6·1 | 39·7 | 58·1% | 41·9% | |
| Phadia 250 | 168 | 8·7 | 2·8 | 12·1 | 14·3% | 85·7% | |
| Orgentec | 43 | 4·7 | 3·0 | 7·4 | 0·0% | 100·0% | |
| Euroimmun | 20 | 10·0 | 7·3 | 28·0 | 95·0% | 5·0% | |
| Phadia Varelisa | 23 | 4·9 | 2·6 | 11·4 | 4·3% | 95·7% | |
| Aesku | 14 | 8·1 | 1·6 | 18·7 | 28·6% | 71·4% | |
| Distribution 122 | All methods | 292 | 12·4 | 1·4 | 45·3 | 72% | 28% |
| Inova | 29 | 25·5 | 8·8 | 45·3 | 96·6% | 3·4% | |
| Phadia 250 | 165 | 12·1 | 1·4 | 17·4 | 89·7% | 10·3% | |
| Orgentec | 42 | 6·0 | 3·3 | 9·4 | 0·0% | 100·0% | |
| Euroimmun | 19 | 14·0 | 10·0 | 44·5 | 100·0% | 0·0% | |
| Phadia Varelisa | 24 | 8·7 | 3·4 | 18·2 | 29·2% | 70·8% | |
| Aesku | 13 | 13·5 | 1·9 | 24·4 | 69·2% | 30·8% |